

# Noel W Clarke

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1329855/publications.pdf>

Version: 2024-02-01

148  
papers

11,684  
citations

41258

49  
h-index

28224

105  
g-index

156  
all docs

156  
docs citations

156  
times ranked

11478  
citing authors

#	ARTICLE	IF	CITATIONS
1	Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 825-836.	0.8	40
2	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. <i>Lancet, The</i> , 2022, 399, 447-460.	6.3	173
3	Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). <i>International Journal of Cancer</i> , 2022, 151, 422-434.	2.3	29
4	Interventions for obstructive uropathy in advanced prostate cancer: a population-based study. <i>BJU International</i> , 2022, , .	1.3	1
5	Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data. <i>PLoS ONE</i> , 2022, 17, e0269192.	1.1	4
6	Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2022, 1, .		124
7	Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5019-5019.	0.8	2
8	Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5050-5050.	0.8	1
9	Maintaining a safe uro-oncological surgical service in the face of the COVID-19 pandemic. <i>Journal of Clinical Urology</i> , 2021, 14, 404-409.	0.1	1
10	Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme. <i>Lancet, The</i> , 2021, 397, 581-591.	6.3	17
11	Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. <i>Circulation</i> , 2021, 144, 1295-1307.	1.6	75
12	Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial. <i>European Urology</i> , 2021, 80, 522-523.	0.9	5
13	Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial. <i>JCO Precision Oncology</i> , 2020, 4, 882-897.	1.5	22
14	The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's M1   RT Comparison. <i>European Urology Oncology</i> , 2020, 3, 412-419.	2.6	9
15	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	0.9	278
16	Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer. <i>JACC: CardioOncology</i> , 2020, 2, 70-81.	1.7	30
17	Diagnosis, Staging and Management of Testis Cancer. , 2020, , 639-652.		0
18	Importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer. <i>BJU International</i> , 2019, 123, 65-73.	1.3	13

#	ARTICLE	IF	CITATIONS
19	The management of testis cancer. <i>Surgery</i> , 2019, 37, 513-523.	0.1	1
20	Abiraterone in "High" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. <i>European Urology</i> , 2019, 76, 719-728.	0.9	142
21	MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 809-818.	0.4	23
22	This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols. <i>Trials</i> , 2019, 20, 264.	0.7	42
23	Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. <i>European Urology</i> , 2019, 76, 115-124.	0.9	203
24	Prostate radiotherapy in newly diagnosed metastatic prostate cancer. <i>Current Opinion in Urology</i> , 2019, 29, 620-628.	0.9	4
25	Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 1-11.	2.6	27
26	Primary Mutational Landscape Linked with Pre-Docetaxel Lactate Dehydrogenase Levels Predicts Docetaxel Response in Metastatic Castrate-Resistant Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 831-841.	1.6	11
27	Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform. <i>BJU International</i> , 2018, 121, 680-683.	1.3	15
28	Magnetic Resonance Imaging and Detection of Metastases in Prostate Cancer: Learning Lessons from History. <i>European Urology</i> , 2018, 73, 92-93.	0.9	0
29	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211.	0.9	488
30	Single-Cell Analysis Identifies LY6D as a Marker Linking Castration-Resistant Prostate Luminal Cells to Prostate Progenitors and Cancer. <i>Cell Reports</i> , 2018, 25, 3504-3518.e6.	2.9	70
31	Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2018, 392, 2353-2366.	6.3	901
32	Treatment-related toxicity in men who received Intensity-modulated versus 3D-conformal radiotherapy after radical prostatectomy: A national population-based study. <i>Radiotherapy and Oncology</i> , 2018, 128, 357-363.	0.3	9
33	Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. <i>New England Journal of Medicine</i> , 2017, 377, 338-351.	13.9	1,315
34	Infrared spectral histopathology using haematoxylin and eosin (H&E) stained glass slides: a major step forward towards clinical translation. <i>Analyst, The</i> , 2017, 142, 1258-1268.	1.7	38
35	Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2017, 84, 88-101.	1.3	128
36	Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1530-1541.	0.8	54

#	ARTICLE	IF	CITATIONS
37	Is it safe to insert a testicular prosthesis at the time of radical orchidectomy for testis cancer: an audit of 904 men undergoing radical orchidectomy. <i>BJU International</i> , 2016, 117, 249-252.	1.3	42
38	High-throughput quantum cascade laser (QCL) spectral histopathology: a practical approach towards clinical translation. <i>Faraday Discussions</i> , 2016, 187, 135-154.	1.6	46
39	The management of testis cancer. <i>Surgery</i> , 2016, 34, 517-526.	0.1	1
40	Estimating the Impact of Randomised Control Trial Results on Clinical Practice: Results from a Survey and Modelling Study of Androgen Deprivation Therapy plus Radiotherapy for Locally Advanced Prostate Cancer. <i>European Urology Focus</i> , 2016, 2, 276-283.	1.6	2
41	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. <i>Lancet, The</i> , 2016, 387, 1163-1177.	6.3	1,570
42	Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. <i>Lancet Oncology, The</i> , 2016, 17, 243-256.	5.1	361
43	Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 348.	3.4	155
44	External urethral sphincter electromyography in asymptomatic women and the influence of the menstrual cycle. <i>BJU International</i> , 2015, 116, 423-431.	1.3	18
45	Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?. <i>BJU International</i> , 2015, 115, 364-372.	1.3	8
46	Cardiovascular risk with androgen deprivation therapy for prostate cancer: Potential mechanisms. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 464-475.	0.8	32
47	Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). <i>European Urology</i> , 2015, 67, 1028-1038.	0.9	340
48	Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival. <i>BJU International</i> , 2014, 114, E70-E73.	1.3	30
49	Advanced prostate cancer: advancing patient care. <i>Trends in Urology &amp; Men's Health</i> , 2014, 5, 40-42.	0.2	0
50	Should centralized histopathological review in penile cancer be the global standard?. <i>BJU International</i> , 2014, 114, 340-343.	1.3	22
51	Automated high-throughput assessment of prostate biopsy tissue using infrared spectroscopic chemical imaging. <i>Proceedings of SPIE</i> , 2014, , .	0.8	8
52	Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial. <i>European Urology</i> , 2014, 66, 799-802.	0.9	56
53	The Melbourne Consensus Statement on the early detection of prostate cancer. <i>BJU International</i> , 2014, 113, 186-188.	1.3	64
54	Assessment of paraffin removal from prostate FFPE sections using transmission mode FTIR-FPA imaging. <i>Analytical Methods</i> , 2014, 6, 1028-1035.	1.3	45

#	ARTICLE	IF	CITATIONS
55	Assessing the challenges of Fourier transform infrared spectroscopic analysis of blood serum. <i>Journal of Biophotonics</i> , 2014, 7, 180-188.	1.1	57
56	Optimisation of an immunohistochemistry method for the determination of androgen receptor expression levels in circulating tumour cells. <i>BMC Cancer</i> , 2014, 14, 226.	1.1	13
57	Balancing Toxicity and Efficacy: Learning from Trials and Treatment Using Antiresorptive Therapy in Prostate Cancer. <i>European Urology</i> , 2014, 65, 287-288.	0.9	3
58	Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma. <i>Clinical Epigenetics</i> , 2013, 5, 16.	1.8	33
59	Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). <i>Lancet Oncology</i> , The, 2013, 14, 306-316.	5.1	83
60	Whole organ cross-section chemical imaging using label-free mega-mosaic FTIR microscopy. <i>Analyst</i> , The, 2013, 138, 7066.	1.7	24
61	FTIR microspectroscopy of selected rare diverse subvariants of carcinoma of the urinary bladder. <i>Journal of Biophotonics</i> , 2013, 6, 73-87.	1.1	38
62	Management of testicular tumours. <i>Surgery</i> , 2013, 31, 535-542.	0.1	0
63	Coming Up for Air: Follow-up and Risk Stratification After Negative Prostate Cancer Screening. <i>European Urology</i> , 2013, 63, 634-635.	0.9	1
64	Prostate radiotherapy for men with metastatic disease: a new comparison in the <sc>S</sc>ySTEMIC <sc>T</sc>herapy in <sc>A</sc>dvancing or <sc>M</sc>etastatic <sc>P</sc>rostate <sc>C</sc>ancer: <sc>E</sc>valuation of <sc>D</sc>rug <sc>E</sc>fficacy (<sc>STAMPEDE</sc>) trial. <i>BJU International</i> , 2013, 111, 697-699.	1.3	28
65	Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells. <i>Endocrine-Related Cancer</i> , 2013, 20, 137-149.	1.6	36
66	<sc>UBE</sc> 2 <sc>QL</sc> 1 is Disrupted by a Constitutional Translocation Associated with Renal Tumor Predisposition and is a Novel Candidate Renal Tumor Suppressor Gene. <i>Human Mutation</i> , 2013, 34, 1650-1661.	1.1	18
67	Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. <i>Lancet Oncology</i> , The, 2012, 13, 549-558.	5.1	100
68	A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2012, 62, 523-533.	0.9	214
69	FTIR microscopy of biological cells and tissue: data analysis using resonant Mie scattering (RMieS) EMSC algorithm. <i>Analyst</i> , The, 2012, 137, 1370.	1.7	117
70	Copper Modulates Zinc Metalloproteinase-Dependent Ectodomain Shedding of Key Signaling and Adhesion Proteins and Promotes the Invasion of Prostate Cancer Epithelial Cells. <i>Molecular Cancer Research</i> , 2012, 10, 1282-1293.	1.5	19
71	Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. <i>Trials</i> , 2012, 13, 168.	0.7	121
72	Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer. <i>BJU International</i> , 2012, 110, 14-22.	1.3	8

#	ARTICLE	IF	CITATIONS
73	Should All Patients Receive Statins to Reduce Cancer Risk After Heart Transplantation?. <i>Circulation</i> , 2012, 126, 391-391.	1.6	1
74	Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma. <i>Epigenetics</i> , 2012, 7, 278-290.	1.3	54
75	Flexible trial design in practice: Dropping and adding arms in STAMPEDE (MRC PR08, CRLUK/06/019)â€”A multiarm, multistage randomized controlled trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 27-27.	0.8	1
76	Early prostate cancer â€” which treatment do men prefer and why?. <i>BJU International</i> , 2011, 107, 1762-1768.	1.3	73
77	Reflections on attempted Angloâ€”Japanese collaboration on STAMPEDE: A randomized controlled trial for men with prostate cancer. <i>International Journal of Urology</i> , 2011, 18, 553-554.	0.5	3
78	Is Population Screening for Prostate Cancer Good or Bad?. <i>European Urology</i> , 2011, 59, 363-364.	0.9	1
79	Targeted Caval Cyto-reduction: Solid Foundations or Shifting Sands?. <i>European Urology</i> , 2011, 59, 919-920.	0.9	1
80	Flexible trial design in practice â€” dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial. <i>Trials</i> , 2011, 12, .	0.7	10
81	Phase II Study of Conformal Hypofractionated Radiotherapy With Concurrent Gemcitabine in Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 733-738.	0.8	155
82	Management of testicular tumours. <i>Surgery</i> , 2010, 28, 610-616.	0.1	0
83	The Motion: GnRH Antagonists are the New Way Forward in Hormonal Therapy. <i>European Urology</i> , 2010, 57, 534-537.	0.9	2
84	Differential Complication Rates Following Radical Cystectomy in the Irradiated and Nonirradiated Pelvis. <i>European Urology</i> , 2010, 57, 1058-1063.	0.9	50
85	Re: Umberto Capitanio, Shahrokh F. Shariat, Hendrik Isbarn, et al. Comparison of Oncologic Outcomes for Open and Laparoscopic Nephroureterectomy: A Multi-Institutional Analysis of 1249 Cases. <i>Eur Urol</i> 2009;56:1â€”9. <i>European Urology</i> , 2010, 57, e34-e35.	0.9	0
86	RMieSâ€”EMSC correction for infrared spectra of biological cells: Extension using full Mie theory and GPU computing. <i>Journal of Biophotonics</i> , 2010, 3, 609-620.	1.1	116
87	Resonant Mie Scattering (RMieS) correction of infrared spectra from highly scattering biological samples. <i>Analyst, The</i> , 2010, 135, 268-277.	1.7	332
88	When Should Radiotherapy Be Used after Radical Prostatectomy? The RADICALS-RT Trial. <i>British Journal of Medical and Surgical Urology</i> , 2010, 3, 190-193.	0.2	5
89	Imaging angiogenesis of genitourinary tumors. <i>Nature Reviews Urology</i> , 2010, 7, 69-82.	1.9	27
90	SR-FTIR spectroscopy of renal epithelial carcinoma side population cells displaying stem cell-like characteristics. <i>Analyst, The</i> , 2010, 135, 3133.	1.7	44

#	ARTICLE	IF	CITATIONS
91	Hoechst 33342 Side Population Identification Is a Conserved and Unified Mechanism in Urological Cancers. <i>Stem Cells and Development</i> , 2009, 18, 1515-1522.	1.1	67
92	Should 5 $\alpha$ -reductase inhibitors be used for prostate disease?. <i>Nature Reviews Urology</i> , 2009, 6, 358-359.	1.9	1
93	Classification of fixed urological cells using Raman tweezers. <i>Journal of Biophotonics</i> , 2009, 2, 47-69.	1.1	58
94	Investigating FTIR based histopathology for the diagnosis of prostate cancer. <i>Journal of Biophotonics</i> , 2009, 2, 104-113.	1.1	97
95	Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. <i>Trials</i> , 2009, 10, 39.	0.7	120
96	Molecular mechanisms of metastasis in prostate cancer. <i>Asian Journal of Andrology</i> , 2009, 11, 57-67.	0.8	78
97	Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. <i>BJU International</i> , 2009, 103, 464-469.	1.3	86
98	CD133: A MARKER OF TRANSIT AMPLIFICATION RATHER THAN STEM CELL PHENOTYPE IN THE PROSTATE?. <i>BJU International</i> , 2009, 103, 856-858.	1.3	8
99	A contemporary standard for morbidity and outcome after radical cystectomy. <i>BJU International</i> , 2009, 104, 628-632.	1.3	25
100	Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. <i>BJU International</i> , 2009, 104, 1580-1584.	1.3	24
101	Response to Letter to the Editor: National Re-Audit of Urology Outpatient Practice in the UK. <i>British Journal of Medical and Surgical Urology</i> , 2009, 2, 263-263.	0.2	0
102	CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma. <i>Molecular Cancer</i> , 2009, 8, 31.	7.9	65
103	Male adnexal tumour of wolffian origin: The first report of metastatic disease. <i>Scandinavian Journal of Urology and Nephrology</i> , 2009, 43, 253-256.	1.4	5
104	Reflection contributions to the dispersion artefact in FTIR spectra of single biological cells. <i>Analyst</i> , 2009, 134, 1171.	1.7	118
105	Management of the Spectrum of Hormone Refractory Prostate Cancer(EAU Lecture,The 97th Annual) Tj ETQq1 1 0,784314 rgBT /Ove	0,0	0,0
106	The Biology of Bone Metastases from Prostate Cancer and the Role of Bisphosphonates. , 2008, , 253-281.		3
107	Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer. <i>BJU International</i> , 2008, 102, 442-445.	1.3	41
108	Aetiology, diagnosis and management of urothelial tumours of the renal pelvis and ureter. <i>BJU International</i> , 2008, 102, 1302-1306.	1.3	9

#	ARTICLE	IF	CITATIONS
109	Editorial Comment on: Noninvasive Detection of Testicular Carcinoma In Situ in Semen Using OCT3/4. <i>European Urology</i> , 2008, 54, 159-160.	0.9	0
110	The Motion: All Men Over the Age of 50 Should be Encouraged to Take a 5 $\alpha$ -Reductase Inhibitor to Prevent Prostate Cancer. <i>European Urology</i> , 2008, 53, 1079-1083.	0.9	2
111	Measurement of elastic properties of prostate cancer cells using AFM. <i>Analyst, The</i> , 2008, 133, 1498.	1.7	247
112	Spectral discrimination of live prostate and bladder cancer cell lines using Raman optical tweezers. <i>Journal of Biomedical Optics</i> , 2008, 13, 064004.	1.4	71
113	Late tissue effects following radiotherapy and neoadjuvant hormone therapy of the prostate measured with quantitative magnetic resonance imaging. <i>Radiotherapy and Oncology</i> , 2008, 88, 127-134.	0.3	26
114	What Does Failure After Surgery or Radiation Mean?. <i>European Urology Supplements</i> , 2008, 7, 410-415.	0.1	4
115	Discrimination of prostate cancer cells and non-malignant cells using secondary ion mass spectrometry. <i>Analyst, The</i> , 2008, 133, 175-179.	1.7	27
116	Characterization of the Hoechst 33342 side population from normal and malignant human renal epithelial cells. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 295, F680-F687.	1.3	76
117	Complications Arising in the Final Year of Life in Men Dying from Advanced Prostate Cancer. <i>Journal of Palliative Medicine</i> , 2007, 10, 705-711.	0.6	43
118	Direct evidence of lipid translocation between adipocytes and prostate cancer cells with imaging FTIR microspectroscopy. <i>Journal of Lipid Research</i> , 2007, 48, 1846-1856.	2.0	133
119	Discrimination of prostate cancer cells by reflection mode FTIR photoacoustic spectroscopy. <i>Analyst, The</i> , 2007, 132, 292.	1.7	45
120	Optical artefacts in transflection mode FTIR microspectroscopic images of single cells on a biological support: the effect of back-scattering into collection optics. <i>Analyst, The</i> , 2007, 132, 750.	1.7	48
121	Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations. <i>Prostate</i> , 2007, 67, 1384-1396.	1.2	102
122	Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): A new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. <i>BJU International</i> , 2007, 99, 1376-1379.	1.3	130
123	Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1743-1753.	2.0	177
124	Skeletal Preservation in Prostate Cancer: The Changing Role of the Urologist. <i>European Urology Supplements</i> , 2006, 5, 871-872.	0.1	2
125	New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer. <i>European Urology Supplements</i> , 2006, 5, 880-885.	0.1	2
126	New Clinical Tools for Urologists: Treatment of Bone Loss. <i>European Urology Supplements</i> , 2006, 5, 877-879.	0.1	0



#	ARTICLE	IF	CITATIONS
127	Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis. <i>European Urology Supplements</i> , 2006, 5, 873-876.	0.1	3
128	The Natural History of Postoperative Renal Function in Patients Undergoing Ileal Conduit Diversion for Cancer Measured Using Serial Isotopic Glomerular Filtration Rate and <sup>99m</sup> Tc-Technetium-Mercaptoacetyltriglycine Renography. <i>Journal of Urology</i> , 2006, 176, 2518-2522.	0.2	41
129	Urine telomerase activity for the diagnosis of bladder cancer. <i>Nature Reviews Urology</i> , 2006, 3, 192-193.	1.4	0
130	The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK. <i>BJU International</i> , 2006, 97, 266-269.	1.3	22
131	Natural History and Treatment of Bone Complications in Prostate Cancer. <i>European Urology</i> , 2006, 49, 429-440.	0.9	78
132	A Correlation of FTIR Spectra Derived from Prostate Cancer Biopsies with Gleason Grade and Tumour Stage. <i>European Urology</i> , 2006, 50, 750-761.	0.9	111
133	Management of the Spectrum of Hormone Refractory Prostate Cancer. <i>European Urology</i> , 2006, 50, 428-439.	0.9	43
134	The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer. <i>European Urology</i> , 2006, 50, 873-878.	0.9	2
135	Management of testicular tumours. <i>Surgery</i> , 2006, 24, 163-168.	0.1	0
136	Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 420-425.	0.4	57
137	Male adnexal tumour of probable Wolffian duct origin. <i>Scandinavian Journal of Urology and Nephrology</i> , 2005, 39, 520-522.	1.4	4
138	The molecular staging of prostate cancer. <i>BJU International</i> , 2004, 94, 1217-1220.	1.3	4
139	Differential Inhibition of Invasion and Proliferation by Bisphosphonates: Anti-Metastatic Potential of Zoledronic Acid in Prostate Cancer. <i>European Urology</i> , 2004, 46, 389-402.	0.9	47
140	The combined application of FTIR microspectroscopy and ToF-SIMS imaging in the study of prostate cancer. <i>Faraday Discussions</i> , 2004, 126, 41.	1.6	78
141	Novel method for the isolation and characterisation of the putative prostatic stem cell. <i>Cytometry</i> , 2003, 54A, 89-99.	1.8	97
142	The Biology and Treatment of Bone Metastases in Prostate Cancer. , 2003, , 931-956.		0
143	A potential role of heat shock proteins and nicotinamide N-methyl transferase in predicting response to radiation in bladder cancer. <i>International Journal of Cancer</i> , 2002, 101, 454-460.	2.3	84
144	Molecular prediction of progression in patients with conservatively managed prostate cancer. <i>Urology</i> , 2001, 58, 762-766.	0.5	12

#	ARTICLE	IF	CITATIONS
145	Scatter factor influences the formation of prostate epithelial cell colonies on bone marrow stroma in vitro. <i>Clinical and Experimental Metastasis</i> , 1999, 17, 331-338.	1.7	24
146	Interaction of prostate epithelial cells from benign and malignant tumor tissue with bone-marrow stroma. , 1998, 34, 203-213.		38
147	Primary prostatic epithelial cell binding to human bone marrow stroma and the role of alpha2beta1 integrin. <i>Clinical and Experimental Metastasis</i> , 1997, 15, 218-227.	1.7	49
148	The Effects of Orchidectomy on Skeletal Metabolism in Metastatic Prostate Cancer. <i>Scandinavian Journal of Urology and Nephrology</i> , 1993, 27, 475-483.	1.4	37